SCHEMBL2011677

SCHEMBL2011677

CCCc1c(OCC(=O)OCC)ccc(C(=O)CN2Cc3cc(C(=N)NO)ccc3C2=O)c1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.35
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
GRM2 Q14416 8/20 0.34
CYSLTR2 Q9NS75 5/20 0.33
CYSLTR1 Q9Y271 5/20 0.33
ALOX15 P16050 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX5 P09917 1/20 0.33
TSHR P16473 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
AOC3 Q16853 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2009693 0.94 ITGB3 (0.35) ITGB3ITGA2BALOX15MEN1KMT2A
SCHEMBL2008552 0.92 CYSLTR2 (0.41) PPARGPPARDPPARAITGB3ITGA2B
SCHEMBL2005638 0.91 ITGB3 (0.38) PPARGPPARDPPARAITGB3ITGA2B
SCHEMBL2005506 0.91 ITGB3 (0.42) PPARGPPARDPPARAITGB3ITGA2B
SCHEMBL2007948 0.91 ITGB3 (0.36) ITGB3ITGA2BGRM2ALOX15MEN1
SCHEMBL2009892 0.90 ITGB3 (0.35) ITGB3ITGA2BALOX15MEN1KMT2A
SCHEMBL2009930 0.89 ITGB3 (0.34) PPARGPPARDPPARAITGB3ITGA2B
SCHEMBL2006718 0.89 ITGB3 (0.35) ITGB3ITGA2BALOX15MEN1KMT2A
SCHEMBL2011017 0.88 AOC3 (0.35) PPARGPPARDPPARAITGB3ITGA2B
SCHEMBL2009096 0.87 ITGB3 (0.34) ITGB3ITGA2BALOX15MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US claimed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US claimed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US claimed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US claimed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP claimed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO claimed
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 PPARG 1067/4885PPARD 948/4885PPARA 1496/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 PPARG 1067/4885PPARD 948/4885PPARA 1496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.